Amarin Corp Plc (AMRN)

[Bouf]

I don’t know that much about promotion of a drug like this with a big new indication, but most of the comments I’ve seen from docs on the ground suggest AMRN would struggle going alone, but this is hard to evaluate with a new best in class offering. Kind of comes down to whether you believe VS will sell itself to a large extent due to its proven CV and other benefits, and largely benign side effects, or whether you think high promotion costs are inevitable. Thoughts on this Q appreciated, as its out of my ballpark.